Log In
BCIQ
Print this Print this
 

ACH-3422

  Manage Alerts
Collapse Summary General Information
Company Achillion Pharmaceuticals Inc.
DescriptionSmall molecule nucleotide prodrug inhibitor of HCV NS5B polymerase
Molecular Target HCV NS5B polymerase
Mechanism of ActionHCV non-structural protein 5B inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat chronic HCV infection
Regulatory Designation
PartnerJohnson & Johnson

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$1,125.0M

0

$900.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/19/2015

$1,125.0M

0

$900.0M

Get a free BioCentury trial today